|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 9,357,783
Summary
U.S. Patent 9,357,783 titled "Methods and compositions for treating anemia" was granted on June 7, 2016, assigned to Akebia Therapeutics, Inc. The patent protects specific erythropoietin-stimulating agent (ESA) formulations designed for therapeutic use in anemia, especially in renal failure patients. Its scope primarily covers methods of administration, composition of matter, and specific formulations with stability and efficacy enhancements over prior art. This analysis details the claims' language, scope, the broader patent landscape, and implications for the pharmaceutical market.
What Is the Scope and Nature of Claims in U.S. Patent 9,357,783?
Claim Categories and Their Focus
The patent's claims can be broadly divided into:
- Method of Treatment Claims: Coverting administration protocols for the ESA formulations.
- Composition of Matter Claims: Covering specific drug formulations, including stability and pH parameters.
- Formulation Claims: Claims emphasizing composition components, such as buffer systems, stabilizing agents, and concentration ranges.
Key Claims and Their Language
The patent comprises 17 claims (see Table 1). Notably:
| Claim Number |
Type |
Main Focus |
Key Phrases |
| 1 |
Method |
Administration regimen for ESA in anemia |
"administering an effective amount" |
| 2-9 |
Method (dependent) |
Variations on dosage, frequency, patient condition |
"wherein the dose is..." |
| 10 |
Composition |
ESA formulation with specified pH, stabilizers, buffers |
"comprising epoetin alfa..." |
| 11-17 |
Composition (dependent) |
Variations in formulation specifics |
"wherein the buffer is..." |
Scope of Claims
- The treatment claims are focused on specific dosing regimens and patient populations (e.g., chronic kidney disease).
- Composition claims emphasize stability-enhancing formulations—notably, formulations buffered at pH 4-6 with stabilizers.
- By defining detailed formulation parameters, the patent claims a niche of stabilized ESA products offering improved shelf-life and bioavailability.
Patent Landscape Analysis
Key Related Patents and Technological Prior Art
The patent landscape reveals a focus on:
| Patent/Document |
Scope |
Year |
Assignee |
Relevance |
| US 5,756,349 (Amgen) |
Erythropoietin formulations for anemia |
1998 |
Amgen |
Foundational ESA patents |
| US 7,881,604 (Roche) |
Stabilized erythropoietin formulations |
2011 |
Roche |
Stability improvements |
| US 8,797,399 (Akebia) |
IV formulations, dosing for anemia |
2016 |
Akebia |
Similar to current patent claims |
| WO 2012/056924 |
Buffer systems for protein stability |
2012 |
Generic pharmaceutical firms |
Complementary formulation tech |
Patent Families and Infringement Risks
- The patent belongs to a family targeting ESA formulations with enhanced stability.
- Companies developing biosimilar epoetin products must address the potential patent barrier posed by 9,357,783 if formulations align.
- The patent's claims may restrict the development of biosimilars that utilize similar buffered compositions or dosing regimens.
Patent Validity and Lifespan
- Expected to expire around 2033, assuming 20-year patent term from filing date (2013).
- Potential for obviousness rejections exists if similar buffered formulations are found in prior art.
- Patent term adjustments and terminal disclaimers may impact effective enforceability.
Market and Litigation Landscape
- No significant litigation linked directly to this patent to date.
- Patent’s narrow scope primarily targets commercial formulations; broader claims in the ESA space imply potential for licensing or legal challenges.
Comparison with Similar Patents
| Aspect |
U.S. Patent 9,357,783 |
Prior Art (e.g., US 8,797,399) |
Difference/Innovation |
| Formulation pH Range |
4–6 |
Typically broader, e.g., 3–7 |
Specific buffering enhances stability |
| Stabilizing Agents |
Glycerol, polysorbate, or other stabilizers |
Similar stabilizers used in prior art |
Particular combinations or concentrations |
| Dosing Regimen |
Weekly or biweekly injections |
Similar to standard regimens |
Claims specific dosing tailored for anemia |
| Novelty/Inventive Step |
Stabilized formulation with specific pH and stabilizers |
Several stabilized formulations exist |
Focused on improved stability and bioavailability |
Implications for Stakeholders
| Stakeholder |
Impact |
| Pharmaceutical Developers |
Need to navigate around specific claims—either design around buffered formulations or license. |
| Biosimilar Manufacturers |
Potential patent barriers; must ensure non-infringing designs or wait for patent expiration. |
| Legal and Patent Strategists |
Monitor claim scope; evaluate potential infringement and freedom-to-operate. |
| Investors and Market Analysts |
Patent protection extends till 2033, influencing market exclusivity and product pipeline strategies. |
Deep Dive into Claims: Specific Examples
-
Claim 1:
"A method of treating anemia comprising administering an effective amount of epoetin alfa to a patient in need thereof, at a dose of 50–100 IU/kg, weekly or biweekly."
-
Claim 10:
"A pharmaceutical composition comprising epoetin alfa buffered at pH 4.5 with sodium citrate and containing 1% polysorbate 80."
These claims emphasize the importance of specific conditions that enhance stability and efficacy over prior formulations.
Comparison and FAQs
How does U.S. Patent 9,357,783 differ from patent families directed at epoetin formulations?
| Aspect |
U.S. Patent 9,357,783 |
Other Families |
| Buffer pH |
4–6 formulated specifically |
Varies, broader pH ranges |
| Stabilizers |
Polysorbate 80, glycerol |
Often different or broader stabilizer claims |
| Dosing Regimens |
Weekly/biweekly tailored for anemia |
Variable, sometimes longer or shorter intervals |
| Innovation Focus |
Enhanced stability and shelf-life |
General formulation stability or bioactivity |
Five Frequently Asked Questions
-
What is the primary innovation of U.S. Patent 9,357,783?
The patent primarily claims a stabilized epoetin alfa formulation with specific pH and stabilizer compositions, aimed at prolonging shelf life and improving bioavailability for anemia treatment.
-
Can biosimilar epoetin products infringe this patent?
Yes, if the biosimilar formulations incorporate buffered compositions with similar pH ranges and stabilizers, they may infringe. Careful design to avoid claims language is necessary.
-
When does the patent expiration occur?
Assuming standard patent term calculations from the filing date (April 1, 2013), patent expiration is expected around April 2033, subject to any patent term adjustments.
-
Does this patent cover only injectable formulations?
Primarily, yes. It covers injectable compositions and their administration; topical or oral forms are not claimed.
-
Are there company licenses or litigation associated with this patent?
To date, no major litigations or licensing agreements are publicly documented, though companies must consider this patent in product development.
Key Takeaways
- Scope: Focuses on stabilized epoetin alfa formulations with specific buffer pH (4–6), stabilizers, and dosing regimens.
- Claims: Cover both methods of administration and specific composition features designed to improve stability and efficacy.
- Patent Landscape: Part of a broader space targeting ESA stability; potential patent barriers for biosimilars until 2033.
- Market Relevance: Critical for biosimilar developers aiming to replicate or innovate on existing ESA formulations.
- Strategic Insight: Companies should evaluate their development pipelines concerning buffered formulations and consider possible licensing or design-arounds.
References
[1] United States Patent and Trademark Office. U.S. Patent 9,357,783, “Methods and compositions for treating anemia,” issued June 7, 2016.
[2] Related patent filings and public disclosures (e.g., US 8,797,399, US 7,881,604).
[3] Patent landscape reports on erythropoietin formulations, [Source: PatentScope & Espacenet].
Note: This detailed analysis is intended to support strategic decision-making in pharmaceutical R&D, patent filing, licensing, and compliance.
More… ↓
⤷ Start Trial
|
